Journal
CIRCULATION
Volume 137, Issue 6, Pages 543-545Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.117.032851
Keywords
blood pressure monitoring; ambulatory; Japan
Funding
- Teijin Pharma, Ltd
- Omron Healthcare Co, Ltd
- Fukuda Denshi
- Bayer Yakuhin, Ltd
- AD Co, Ltd
- Daiichi Sankyo Co, Ltd
- Mochida Pharmaceutical Co, Ltd
- EA Pharma
- Boehringer Ingelheim Japan Inc
- Tanabe Mitsubishi Pharma Corp
- Shionogi Co, Ltd
- MSD KK
- Sanwa Kagaku Kenkyusho Co, Ltd
- Bristol-Myers Squibb KK
- Grants-in-Aid for Scientific Research [26293192] Funding Source: KAKEN
Ask authors/readers for more resources
The 2017 American Heart Association/American College of Cardiology (AHA/ACC) guidelines for the prevention, detection, evaluation, and management of high blood pressure (BP) in adults were recently released. 1 The core concept in these guidelines is earlier and tighter BP control over 24 hours, with the aim of providing more sustained target organ protection and cardiovascular disease prevention. These guidelines lower the threshold of hypertension diagnosis and target BP levels to 130/80 mm Hg. This direction of strict BP control with a new definition and universal target goal for hypertension will be the topic of debate among the guideline developing committee members of the Japanese Society of Hypertension.(2)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available